US OptionsDetailed Quotes
EXAS240517P77500
- 17.70
- 0.000.00%
15min DelayClose May 17 16:00 ET
0.00High0.00Low
17.70Open17.70Pre Close0 Volume1 Open Interest77.50Strike Price0.00Turnover0.00%IV0.34%PremiumMay 17, 2024Expiry Date27.12Intrinsic Value100Multiplier-1DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma1.87Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Exact Sciences Stock Discussion
Sign in to post a comment
$Exact Sciences(EXAS.US$ Good opportunity to buy after correction, "not today" I shall buy in next week once volatility minimized. Good AI stoks but you can see good return not before 2025. I am bullish on it and it will remain my best pick for next 3-5 years invetment tenure.
2
Exact Sciences' progress has failed to meet high market expectations, yet its consistent revenue growth suggests it may be worth further investigation. The company's performance has underperformed the broader market, which gained around 31%.
2
The company's strained balance sheet and lack of EBIT level profitability heighten risk. Its debt management and growth rate are key concerns, with faster growth expected from unprofitable firms.
Exact Sciences' low P/S ratio is due to its poor revenue outlook. Investors foresee limited growth, thus are only willing to pay less for the stock, making a strong share price rise unlikely.
Exact Sciences' growth rate is somewhat slow, showing a 20% rise in revenue while lacking profitability at an EBIT level. Considerable liabilities and negative EBIT results make its financial status seem precarious and risky.
Impressive annual returns suggest the company's improved performance. Its focus on revenue growth proves strategic, although further profitability analysis is wise given the substantial share appreciation.
Gapping up
$Coinbase(COIN.US$+2.38% (The crypto exchange stock climbed in premarket trading, seemingly aided by the surge in bitcoin's 7.8% climb. Coinbase has faced a multiple headwinds recently, from an ongoing spat with the U.S. Securities and Exchange Commission to BlackRock's launch of its own bitcoin exchange-traded fund.)
$MicroStrategy(MSTR.US$+2.58% (Shares have climbed more than 121% so far in 2023 and 8.7% over the past...
$Coinbase(COIN.US$+2.38% (The crypto exchange stock climbed in premarket trading, seemingly aided by the surge in bitcoin's 7.8% climb. Coinbase has faced a multiple headwinds recently, from an ongoing spat with the U.S. Securities and Exchange Commission to BlackRock's launch of its own bitcoin exchange-traded fund.)
$MicroStrategy(MSTR.US$+2.58% (Shares have climbed more than 121% so far in 2023 and 8.7% over the past...
18
$ARK Innovation ETF(ARKK.US$ Cathie Wood telling us she sold $NVIDIA(NVDA.US$ the leader in Ai to buy $UiPath(PATH.US$ $Twilio(TWLO.US$ $Exact Sciences(EXAS.US$ I didn’t know $Twilio(TWLO.US$ was an Ai company lol.
She’s the anti Peter Lynch
"SELLING YOUR WINNERS AND HOLDING YOUR LOSERS IS LIKE
CUTTING THE FLOWERS AND WATERING THE WEEDS."![]()
![]()
![]()
She’s the anti Peter Lynch
"SELLING YOUR WINNERS AND HOLDING YOUR LOSERS IS LIKE
CUTTING THE FLOWERS AND WATERING THE WEEDS."
6
2
$ARK Innovation ETF(ARKK.US$ $ARK Next Generation Internet ETF(ARKW.US$ $ARK Autonomous Technology & Robotics ETF(ARKQ.US$
ARK Invest’s 13F portfolio value increased from $11.54B to $14.55B this quarter.
They increased Tesla, Coinbase Global, Block, Unity Software, and Ginkgo Bioworks while decreasing Exact Sciences, Twilio, and NVIDIA during the quarter.
The top three positions are Tesla, Roku, and Zoom Video, and they add up to ~...
ARK Invest’s 13F portfolio value increased from $11.54B to $14.55B this quarter.
They increased Tesla, Coinbase Global, Block, Unity Software, and Ginkgo Bioworks while decreasing Exact Sciences, Twilio, and NVIDIA during the quarter.
The top three positions are Tesla, Roku, and Zoom Video, and they add up to ~...
9
1
No comment yet
5060 : nobody cares clown
Sikander KHANOP 5060: Dear tell me one example where I was wrong.